DexCom
DXCM
902 hedge funds and large institutions have $34.4B invested in DexCom in 2023 Q3 according to their latest regulatory filings, with 111 funds opening new positions, 346 increasing their positions, 334 reducing their positions, and 153 closing their positions.
21% more funds holding in top 10
Funds holding in top 10: 14 → 17 (+3)
4% more repeat investments, than reductions
Existing positions increased: 346 | Existing positions reduced: 334
0.28% less ownership
Funds ownership: 95.2% → 94.92% (-0.28%)
5% less funds holding
Funds holding: 954 → 902 (-52)
14% less call options, than puts
Call options by funds: $503M | Put options by funds: $582M
27% less capital invested
Capital invested by funds: $47.4B → $34.4B (-$13B)
27% less first-time investments, than exits
New positions opened: 111 | Existing positions closed: 153
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$393M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$209M |
| 3 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
+$164M |
| 4 |
Holocene Advisors
New York
|
+$111M |
| 5 |
Neuberger Berman Group
New York
|
+$105M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$819M |
| 2 |
Jennison Associates
New York
|
-$337M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$301M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$176M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$101M |
DXCM Hedge Fund Activity: Q3 2023 in Review
902 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q3 2023, worth a combined $34.4B — down 27% from $47.4B a quarter earlier.
Sellers outnumbered buyers: 153 funds closed out of DXCM and 111 opened new positions — a net loss of 42 holders — while 334 trimmed existing stakes and 346 added.
The largest buyer was Capital Research Global Investors, adding an estimated $393M. The largest seller was JP Morgan Chase, cutting an estimated $819M.
- 902 institutional investors held DexCom (DXCM) as of Q3 2023, down from 954 in Q2 2023.
- Funds reported $34.4B of DexCom stock for Q3 2023, down 27% quarter-over-quarter.
- 111 funds opened new DexCom positions in Q3 2023 and 153 closed out, a net change of -42 holders.
- The largest DexCom buyer in Q3 2023 was Capital Research Global Investors, an estimated $393M added.
- The largest DexCom seller in Q3 2023 was JP Morgan Chase, an estimated $819M sold.
Based on aggregated 13F filings for Q3 2023.